Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

by NASDAQ Market News June 22, 2020

NASDAQ Market News
Click here to email author

Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

In Vitro Diagnostics (IVD) Market Worth $87.21 Billion by 2024, Growing at a CAGR of 5.7% – Global Opportunity Analysis and Industry Forecasts by Meticulous Research®

Ads